Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

McMaster University

$105,000.00

Investigating and harnessing the immunoregulatory function of interferons in viral-induced immunopathology

FY 2021-22

Summary
In response to viral infections, immune activation and inflammation must be tightly regulated as too little will impair clearance of an infection, however excessive immune activation can cause irreparable tissue damage and hinder disease tolerance. In the absence of a suitable vaccine, we must be able to effectively treat severe infections, however, our ability to treat viral-induced immunopathology remains poor. Key to regulating our damaging immune responses to all viral infections are our type I and III interferon responses. Attempts to harness type I interferons in the past have been severely limited by the timeliness required for effective type I interferon therapy. In contrast, while the immunoregulatory type III IFNs are poorly defined, growing evidence suggests their high flexibility as a therapeutic avenue, and their potent ability to suppress unwanted immune responses. Both Ebola virus outbreaks and the COVID-19 pandemic have shown that the ability to produce potent interferon response correlates with improved viral clearance and reduced inflammation and disease severity, and demographics more likely to experience severe infections, such as the elderly, have also been demonstrated to elicit a weaker interferon response during infection. Thus, the potential for interferons to be harnessed as a therapeutic due to their immunoregulatory capacities remains highly promising, yet unexploited. In this project, we will be investigating the mechanisms through how type III interferons are able to suppress viral-induced immunopathology and assess how they can be used safely in a therapeutic capacity. We will also investigate the role interferons may play in determining disease susceptibility in aging populations. By understanding the full type III interferons play in regulating disease tolerance, can develop novel therapeutics, that would be applicable to any viral infection, and would prepare us for any current and future epidemic.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
458563
Name
Feng Emily
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating and harnessing the immunoregulatory function of interferons in viral-induced immunopathology
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Disase Tolerance; Immune Regulation; Type I And Iii Interferons; Viral Infection
Abstract
In response to viral infections, immune activation and inflammation must be tightly regulated as too little will impair clearance of an infection, however excessive immune activation can cause irreparable tissue damage and hinder disease tolerance. In the absence of a suitable vaccine, we must be able to effectively treat severe infections, however, our ability to treat viral-induced immunopathology remains poor. Key to regulating our damaging immune responses to all viral infections are our type I and III interferon responses. Attempts to harness type I interferons in the past have been severely limited by the timeliness required for effective type I interferon therapy. In contrast, while the immunoregulatory type III IFNs are poorly defined, growing evidence suggests their high flexibility as a therapeutic avenue, and their potent ability to suppress unwanted immune responses. Both Ebola virus outbreaks and the COVID-19 pandemic have shown that the ability to produce potent interferon response correlates with improved viral clearance and reduced inflammation and disease severity, and demographics more likely to experience severe infections, such as the elderly, have also been demonstrated to elicit a weaker interferon response during infection. Thus, the potential for interferons to be harnessed as a therapeutic due to their immunoregulatory capacities remains highly promising, yet unexploited. In this project, we will be investigating the mechanisms through how type III interferons are able to suppress viral-induced immunopathology and assess how they can be used safely in a therapeutic capacity. We will also investigate the role interferons may play in determining disease susceptibility in aging populations. By understanding the full type III interferons play in regulating disease tolerance, can develop novel therapeutics, that would be applicable to any viral infection, and would prepare us for any current and future epidemic.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Feng, Emily
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McMaster University - $105,000 Grant (2021-22) | Canada Spends